A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) (NCT07176390)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (5 items).
Location: Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018) — Glendale, Arizona
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: The main exclusion criteria include but are not limited to the following:
- Has any arthritis with onset before age 17 years or current diagnosis of inflammatory joint disease other than RA (such as, but not limited to, psoriatic arthritis, systemic lupus erythematosus, gout, systemic sclerosis, myositis, pseudogout, etc) or any other condition that may, in the judgment of the investigator, interfere with the assessment of RA
- Has a history of cancer (except fully treated nonmelanoma skin cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \<5 years before randomization
- Has any active infection
- Has known allergies, hypersensitivity, or intolerance to tulisokibart or its excipients
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018) — Glendale, Arizona
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033) — Mesa, Arizona
- Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024) — La Palma, California
- Tekton Research, LLC. ( Site 1008) — Fort Collins, Colorado
- Sweet Hope Research Specialty, Inc ( Site 1015) — Hialeah, Florida
- HMD Research LLC ( Site 1016) — Orlando, Florida
- Greater Chicago Specialty Physicians - Orland Park ( Site 1043) — Orland Park, Illinois
- AA Medical Research Center ( Site 1027) — Grand Blanc, Michigan
- Kansas City Physician Partners ( Site 1032) — Kansas City, Missouri
- Physician Research Collaboration, LLC ( Site 1002) — Lincoln, Nebraska
- altoona center for clinical research ( Site 1005) — Duncansville, Pennsylvania
- Rheumatology Specialty Center ( Site 1030) — Willow Grove, Pennsylvania
- AARA Clinical Research - Murfreesboro Medical Clinic ( Site 1034) — Murfreesboro, Tennessee
- Rheumatology Associates ( Site 1026) — Arlington, Texas
- Epic Medical Research ( Site 1004) — Red Oak, Texas
- Advanced Rheumatology of Houston - Woodlands ( Site 1000) — The Woodlands, Texas
- Mount Sinai Hospital ( Site 1102) — Toronto, Ontario
- CIUSSS de l'Estrie - CHUS, Hotel-Dieu de Sherbrooke ( Site 1106) — Sherbrooke, Quebec
- Centre de Recherche Musculo-Squelettique ( Site 1101) — Trois-Rivières, Quebec
- Centro de Estudios GyC ( Site 1206) — Santiago, Region M. de Santiago
- Clinica Dermacross ( Site 1203) — Santiago, Region M. de Santiago
- CECIM ( Site 1208) — Santiago, Region M. de Santiago
- Pontificia Universidad Catolica de Chile-CICUC ( Site 1209) — Santiago, Region M. de Santiago
- Peking University First Hospital ( Site 2511) — Beijing, Beijing Municipality
- The First Affiliated Hospital of Xiamen University. ( Site 2510) — Xiamen, Fujian
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Arthritis, Rheumatoid
- Chronic Pain in Rheumatoid Arthritis — Denver, Colorado
- Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis — Ann Arbor, Michigan
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis — Boston, Massachusetts
- R-2487 in Patients With Rheumatoid Arthritis — San Diego, California
- INFINITY™ With ADAPTIS™ Technology Study — Gilbert, Arizona
Explore by condition: All Arthritis, Rheumatoid clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.